2-Ethoxy-3-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]-3H-benzoimidazole-4-carboxylic acid

This is the name of 2-ethoxy-3- [[4- [2- (1H-tetrazolyl-5-yl) phenyl] phenyl] methyl] -3H-benzimidazole-4-carboxylic acid. To clarify its chemical structure, let me explain in detail.
In this compound, the core is the benzimidazole ring, which is formed by fusing the benzene ring with the imidazole ring. At position 3 of the benzimidazole ring, a complex side chain is connected. The side chain starts from a methylene, and the methylene is connected to a structure composed of two benzene rings, one of which is connected at position 4 to the 2 - (1H-tetrazole-5-yl) phenyl part of the other benzene ring. At position 4 of the benzimidazole ring, a carboxyl group is connected. At position 2 of the benzimidazole ring, ethoxy is connected.
In the structure of this compound, tetrazolyl, benzimidazole ring, carboxyl, ethoxy and other functional groups are connected to each other, which together constitute its unique chemical structure. The interaction between the various parts endows the compound with specific chemical and physical properties, which may be used in the fields of organic synthesis and medicinal chemistry. Its complex structure also makes it challenging and meaningful to study its properties and reactions.

2-Ethoxy-3- [[4- [2- (1H-tetrazolium-5-yl) phenyl] phenyl] methyl] -3H-benzimidazole-4-carboxylic acid, this is an organic compound. Looking at its structure, it can be seen that it has specific physical properties.
This compound is in a solid state at room temperature and pressure. Due to the presence of many cyclic structures and polar groups in the molecule, its melting point may be relatively high. Among them, benzimidazole rings, phenyl groups and tetrazolium rings build a rigid skeleton, which enhances the intermolecular force, thereby increasing the melting point. As for the exact melting point value, it still needs to be accurately determined by experiment.
In terms of solubility, since its molecule contains carboxylic acid groups, which are polar hydrophilic groups, it may have a certain solubility in polar solvents such as methanol, ethanol, water, etc. However, there are also a large number of non-polar aromatic ring structures in the molecule, which will limit its solubility in water. In less polar organic solvents such as dichloromethane and ether, the solubility may be relatively limited.
In appearance, it is inferred according to its structure and the characteristics of similar compounds, or it is a white to light yellow solid powder. Because there is no obvious chromophore in the molecular structure, if there is no special crystal form to cause light scattering, it is likely to appear white. However, if there are impurities or crystal differences in the synthesis process, the color may change slightly, and it may be light yellow.
In terms of density, due to the tight molecular structure and relatively large atomic weight, the density may be higher than that of common organic solvents. However, the exact density value also needs to be accurately measured experimentally.
Its physical properties are affected by the interaction of various groups in the molecular structure. Aromatic rings provide rigidity and non-polarity, while polar groups give them a certain hydrophilicity and related physical properties.

This compound is named 2-ethoxy-3- [4- [2- (1H-tetrazolium-5-yl) phenyl] phenyl] -3H-benzimidazole-4-carboxylic acid. In the field of pharmacy, compounds with such structures often exhibit unique medicinal value.
Looking at its structure, tetrazolium groups often have the characteristics of bioelectrons and other exosomes, which can simulate some functions of carboxyl groups and help improve the interaction between compounds and biological targets. Benzimidazole structures are commonly found in a variety of biologically active molecules, which can specifically bind to the activity checking points of specific receptors or enzymes.
In previous studies, compounds containing such structures have been explored for the treatment of cardiovascular diseases. Because tetrazole and benzimidazole can partially affect the angiotensin II receptor, thereby regulating blood pressure. For example, by precisely binding to the receptor, it blocks the physiological effect of angiotensin II, promoting vasodilation and achieving the effect of lowering blood pressure.
At the same time, it also has potential uses in the field of inflammation-related diseases. Because of its structure or can regulate key targets in the inflammatory signaling pathway, it inhibits the release of inflammatory mediators, thereby reducing the inflammatory response. For example, in the study of chronic inflammatory diseases such as arthritis, similar structural compounds have shown a regulatory effect on the expression of inflammatory factors, and are expected to become drugs to relieve inflammatory symptoms.
In addition, in tumor treatment research, such compounds have also emerged. Its structure may interfere with tumor cell proliferation, apoptosis-related signaling, and inhibit tumor cell growth. As some studies have found, compounds with similar structural combinations of benzimidazole and tetrazole can induce tumor cell apoptosis, providing new ideas for the development of tumor therapeutic drugs.
It can be seen that 2-ethoxy-3- [4- [2- (1H-tetrazolium-5-yl) phenyl] phenyl] methyl] -3H-benzimidazole-4-carboxylic acid has great potential in many directions of pharmaceutical research and development, and is expected to be developed into an effective drug for treating a variety of diseases through in-depth research.

Fu 2 - Ethoxy - 3 - [[4 - [2 - (1H - tetrazol - 5 - yl) phenyl] phenyl] methyl] - 3H - benzoimidazole - 4 - carboxylic acid, there are various synthesis methods. One method is to use 4- [2- (1H - tetrazol - 5 - yl) phenyl] benzaldehyde and 2 - ethoxy - 3 - methyl - 3H - benzoimidazole - 4 - carboxylic acid as raw materials, through condensation reaction, to form its skeleton. This condensation reaction usually requires a suitable solvent, such as ethanol or dichloromethane, accompanied by a base agent, such as potassium carbonate or sodium carbonate, to promote the reaction.
Or, first prepare a phenyl halide containing tetrazol-5-yl, and a derivative with benzimidazole structure. The coupling reaction of metal catalysis, such as palladium-catalyzed coupling, can connect the two. Among them, palladium catalysts such as tetra (triphenylphosphine) palladium, the reaction conditions need to be controlled by temperature, time, etc., so that the reaction is smooth and the yield is considerable.
Furthermore, it can be reacted with Grignard reagents such as 2 - ethoxy - 3- (bromomethyl) - 3H - benzoimidazole - 4 - carboxylic acid and 4 - [2- (1H - tetrazol - 5 - yl) phenyl] phenyl - magnesium bromide to form the target compound. However, this reaction requires strict reaction environment, and anhydrous and anaerobic conditions are required to avoid the decomposition of Grignard reagents.
All synthesis methods have their own advantages and disadvantages. The method of condensation, the raw materials are easy to prepare, but the reaction selectivity may need to be precisely controlled; the method of coupling, the structure can be precisely connected, but the catalyst cost is higher; although the Grignard reaction can build complex structures, the reaction conditions are complicated. Synthesizers need to choose an appropriate method to produce this compound according to actual needs, such as the availability of raw materials, cost considerations, and yield expectations.

2-Ethoxy-3 - [ [ 4- [2- (1H-tetrazole-5-yl) phenyl] phenyl] methyl] -3H-benzimidazole-4-carboxylic acid, this compound has potential significance in the field of pharmaceutical research and development, or involves the creation of therapeutic drugs such as cardiovascular diseases.
Looking at its market prospects, in today's society, cardiovascular diseases have become a major global health threat, and the patient population is large and growing. If this compound can be developed into a drug, targeting specific cardiovascular diseases, or bringing new hope to patients, the market demand is expected to be considerable.
From the research and development perspective, with the advancement of science and technology and the in-depth understanding of disease mechanisms, drug research and development technologies continue to innovate. In-depth research on this compound may be able to optimize its pharmacological properties with new methods and technologies, such as improving bioavailability and enhancing targeting. R & D investment has increased, and many scientific research institutions and pharmaceutical companies have actively participated, or accelerated its transformation process from laboratory to market.
However, its listing also faces challenges. Strict regulations and supervision require a large number of preclinical and clinical trials to prove its safety and effectiveness, which is time-consuming and costly. And competition is intense. The development of drugs with similar mechanisms of action may already be on the way. If you want to stand out, you need to demonstrate unique advantages.
Overall, 2 - ethoxy - 3 - [ [ 4 - [2 - (1H - tetrazolium - 5 - yl) phenyl] phenyl] methyl] - 3H - benzimidazole - 4 - carboxylic acid market prospects both opportunities and challenges, if research and development successfully overcome the difficulties, in the pharmaceutical market or can occupy a place, benefit patients.